Utilization of anti-Parkinson drugs in Australia: 1995–2009

Hollingworth, Samantha A., Rush, Amanda, Hall, Wayne D. and Eadie, Mervyn J. (2011) Utilization of anti-Parkinson drugs in Australia: 1995–2009. Pharmacoepidemiology and Drug Safety, 20 5: 450-456. doi:10.1002/pds.2114

Author Hollingworth, Samantha A.
Rush, Amanda
Hall, Wayne D.
Eadie, Mervyn J.
Title Utilization of anti-Parkinson drugs in Australia: 1995–2009
Journal name Pharmacoepidemiology and Drug Safety   Check publisher's open access policy
ISSN 1099-1557
Publication date 2011
Sub-type Article (original research)
DOI 10.1002/pds.2114
Volume 20
Issue 5
Start page 450
End page 456
Total pages 7
Place of publication West Sussex, United Kingdom
Publisher John Wiley & Sons
Collection year 2012
Language eng
Formatted abstract
Purpose: To examine trends in the prescribing of anti-Parkinsonian drugs (APD) in Australia from 1995 to 2009.
Methods: We analyzed the Medicare Australia and Drug Utilisation Sub-Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data.
Results: Dispensed use of levodopa+carbidopa remained steady from 1995 to 2009 (0.76-0.82 DDD/1000 population/day); levodopa+benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa+carbidopa+entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa+carbidopa was the most widely used agent, followed by levodopa+benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60-69 years. Age-adjusted utilization was slightly higher in males than females.
The amount of levodopa dispensed has slowly increased with levodopa+benserazide increasing faster than levodopa+carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot-related serosal adverse effects was more widely appreciated. Use of centrally acting anti-cholinergics decreased over a period of time when use of atypical anti-psychotic agents increased.
Keyword Anti-Parkinson drugs
Parkinson's disease
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 14 Oct 2011, 15:47:09 EST by Geraldine Fitzgerald on behalf of School of Public Health